Guanwei Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guanwei Fan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aodi Fan
State Key Laboratory of Component‐Based Chinese Medicine & Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae for the Ministry of Education Tianjin University of Traditional Chinese Medicine Tianjin China
1 shared publication - Baolei Dou
Tianjin University of Traditional Chinese Medicine Tianjin China
1 shared publication - Chuanrui Ma
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 300193 Tianjin, China
1 shared publication - Hanqing Lin
State Key Laboratory of Modern Chinese Medicine, Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae for the Ministry of Education, Tianjin University of Traditional Chinese Medicine, 301617 Tianjin, China
1 shared publication - Jiali Gan
School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
1 shared publication Ke Yang
State Key Laboratory of Modern Chinese Medicine, Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae for the Ministry of Education, Tianjin University of Traditional Chinese Medicine, 301617 Tianjin, China
1 shared publication
Latest Publications
- 19 August 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (23) , 6847-6864
Calpain‐2 as a therapeutic target for sodium danshensu in mitigating myocardial ischaemia–reperfusion injury
Background and Purpose: Myocardial reperfusion, a life‐saving intervention after heart attacks, paradoxically induces myocardial ischaemia–reperfusion injury (MIRI), a detrimental condition. MIRI is a persistent clinical challenge stemming from an incomplete understanding of its pathogenic mechanisms. This study aimed to identify the direct molecular target of sodium danshensu (SDSS) and elucidate the underlying mechanism by which it attenuates MIRI. Experimental Approach: We integrated in vivo (left anterior descending artery ligation and reperfusion model) and in vitro (hypoxia‐reoxygenation model) approaches with proteomic profiling (HuProt™ microarray and liquid chromatography‐tandem mass spectrometry [LC–MS/MS]), biophysical validation (cellular thermal shift assay [CETSA] and drug affinity responsive target stability [DARTS]) and molecular docking. The functional role of the identified target, calpain‐2 (CAPN2) was further confirmed through pharmacological inhibition and genetic overexpression experiments. Key Results: SDSS administration significantly attenuated MIRI in in vivo and in vitro models. Using direct target‐related technologies, CAPN2 was identified as a direct binding target of SDSS and was shown to be highly expressed in the heart. According to pathway enrichment analysis, CAPN2‐mediated apoptosis in cardiomyocytes was a primary mechanism by which SDSS alleviated MIRI. The cardioprotective effects of SDSS were replicated by a selective CAPN2 inhibitor and abolished upon CAPN2 overexpression. Conclusions and Implications: SDSS confers cardioprotection by directly targeting and inhibiting CAPN2. This establishes CAPN2 as a potential therapeutic target for MIRI and provides a mechanistic basis for the development of SDSS‐based therapies.
- 19 August 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (23) , 6847-6864
Calpain‐2 as a therapeutic target for sodium danshensu in mitigating myocardial ischaemia–reperfusion injury
Background and Purpose: Myocardial reperfusion, a life‐saving intervention after heart attacks, paradoxically induces myocardial ischaemia–reperfusion injury (MIRI), a detrimental condition. MIRI is a persistent clinical challenge stemming from an incomplete understanding of its pathogenic mechanisms. This study aimed to identify the direct molecular target of sodium danshensu (SDSS) and elucidate the underlying mechanism by which it attenuates MIRI. Experimental Approach: We integrated in vivo (left anterior descending artery ligation and reperfusion model) and in vitro (hypoxia‐reoxygenation model) approaches with proteomic profiling (HuProt™ microarray and liquid chromatography‐tandem mass spectrometry [LC–MS/MS]), biophysical validation (cellular thermal shift assay [CETSA] and drug affinity responsive target stability [DARTS]) and molecular docking. The functional role of the identified target, calpain‐2 (CAPN2) was further confirmed through pharmacological inhibition and genetic overexpression experiments. Key Results: SDSS administration significantly attenuated MIRI in in vivo and in vitro models. Using direct target‐related technologies, CAPN2 was identified as a direct binding target of SDSS and was shown to be highly expressed in the heart. According to pathway enrichment analysis, CAPN2‐mediated apoptosis in cardiomyocytes was a primary mechanism by which SDSS alleviated MIRI. The cardioprotective effects of SDSS were replicated by a selective CAPN2 inhibitor and abolished upon CAPN2 overexpression. Conclusions and Implications: SDSS confers cardioprotection by directly targeting and inhibiting CAPN2. This establishes CAPN2 as a potential therapeutic target for MIRI and provides a mechanistic basis for the development of SDSS‐based therapies.
- Open Access
- 19 May 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (5) , 49006
Role of Macrophage Efferocytosis in Cardiovascular Homeostasis and Disease
Cardiovascular diseases (CVDs) are the primary cause of mortality globally. The Global Burden of Disease Study indicates that CVDs account for one-third of all global deaths, with a notable 18.17% increase in their incidence over the last decade. Despite the widespread use and proven effectiveness of therapies like antiplatelet agents, lipid-lowering drugs, anticoagulants, and percutaneous coronary intervention (PCI) in managing risk factors, the long-term prognosis of patients remains suboptimal. The prevailing academic viewpoint asserts that chronic inflammation and dysregulated apoptosis lead to the accumulation of apoptotic cells or fragments, triggering inflammatory injury and oxidative stress. Efferocytosis, encompassing the recognition, engulfment, and degradation of apoptotic cells by phagocytes, is essential for preserving tissue homeostasis and limiting excessive inflammation in this context. Macrophages, being professional phagocytes, demonstrate the highest efficiency and precision in clearing apoptotic cells. Hence, this review will center on macrophage-mediated efferocytosis, systematically investigating its roles and mechanisms in the pathogenesis and progression of CVDs.
- 19 May 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (5) , 49006
Open AccessRole of Macrophage Efferocytosis in Cardiovascular Homeostasis and Disease
Cardiovascular diseases (CVDs) are the primary cause of mortality globally. The Global Burden of Disease Study indicates that CVDs account for one-third of all global deaths, with a notable 18.17% increase in their incidence over the last decade. Despite the widespread use and proven effectiveness of therapies like antiplatelet agents, lipid-lowering drugs, anticoagulants, and percutaneous coronary intervention (PCI) in managing risk factors, the long-term prognosis of patients remains suboptimal. The prevailing academic viewpoint asserts that chronic inflammation and dysregulated apoptosis lead to the accumulation of apoptotic cells or fragments, triggering inflammatory injury and oxidative stress. Efferocytosis, encompassing the recognition, engulfment, and degradation of apoptotic cells by phagocytes, is essential for preserving tissue homeostasis and limiting excessive inflammation in this context. Macrophages, being professional phagocytes, demonstrate the highest efficiency and precision in clearing apoptotic cells. Hence, this review will center on macrophage-mediated efferocytosis, systematically investigating its roles and mechanisms in the pathogenesis and progression of CVDs.